Canadian LPs Expand European Medical Cannabis Footprint as Demand Grows

Supply Gap Drives Canadian Export Strategy

European medical cannabis demand is growing faster than local cultivation can scale, opening a structural advantage for Canadian LPs with EU-GMP certification. Germany enrolled more than 340,000 medical cannabis patients as of Q2 2026, up 28% year-over-year. Domestic German cultivation facilities? Still stuck in licensing limbo under BfArM's revised tender process. Poland's patient count crossed 85,000 in July, but the country has no licensed domestic growers.

Canadian producers hold a first-mover edge. Most major LPs secured EU-GMP certification between 2021 and 2024, positioning them as turnkey suppliers when European demand began accelerating in 2025. Tilray Brands, Canopy Growth, and Aurora Cannabis now collectively supply an estimated 40% of Germany's imported flower and oil, according to data from the German Federal Institute for Drugs and Medical Devices.

The regulatory arbitrage is clear: Canadian facilities can export EU-GMP product today, while European applicants wait 18-36 months for cultivation licenses.

Distribution Partnerships Replace Direct-to-Pharmacy Models

Canadian LPs are shifting from direct export to joint ventures and white-label agreements with European distributors. This model reduces logistics friction and accelerates market entry. Tilray operates a 2.4-million-square-foot EU-GMP facility in Portugal, but also partners with Germany's Cannamedical and UK-based Sapphire Medical Clinics for last-mile distribution.

Key partnership structures include:

• White-label supply: Canadian LP manufactures; European partner brands and distributes under local pharmacy networks.
• Joint cultivation: Canadian LP provides genetics and SOPs; European partner operates the grow under shared revenue.
• Exclusive distribution: Canadian LP retains brand; European distributor handles regulatory filings and pharmacy relationships.

Aurora Cannabis signed a five-year exclusive distribution deal with Poland's Ethica Health Group in June 2026, targeting the country's underserved patient base. The agreement gives Aurora access to 1,200 Polish pharmacies without requiring a local cultivation footprint.

Germany Remains the Anchor Market

Germany accounts for roughly 60% of European medical cannabis sales by volume, making it the must-win market for Canadian exporters. The country's April 2024 rescheduling of cannabis to a controlled narcotic (rather than a prohibited substance) streamlined prescribing. Patient enrollment has climbed every quarter since. Monthly flower sales in Germany now exceed 12,000 kilograms, with imports filling 70% of that demand.

BfArM's domestic cultivation tender—intended to license 10 German growers by 2025—has stalled. Only three applicants received provisional licenses. None have begun commercial production. That delay extends the runway for Canadian imports, and Canopy Growth's Spektrum Cannabis brand holds an estimated 18% share of the German medical market, the largest of any single supplier.

For full background on this story, see the CannIntel topic hub on the European Medical Cannabis Market.

Regulatory Headwinds and the INCB Watch

Canadian export growth faces two structural risks: tightening EU-GMP audits and INCB import-quota scrutiny. The International Narcotics Control Board tracks cannabis import volumes under the 1961 Single Convention, and several EU member states have flagged concerns about over-reliance on non-EU suppliers. France and Italy both proposed domestic-preference rules in 2025, though neither has been enacted.

EU-GMP re-certification is becoming more rigorous. Health Canada's mutual recognition agreement with the European Medicines Agency expires in December 2026, and renewal negotiations are stalled over pesticide-residue testing standards. If the MRA lapses, Canadian LPs will need to undergo full EU-GMP audits by European regulators—a process that can take 12-18 months and cost upward of CAD 500,000 per facility.

The political variable? Germany's coalition government. If the CDU/CSU returns to power in the 2027 federal election, medical cannabis policy could tighten, including stricter import quotas favoring EU producers.